Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 15 of the 29 sources its claims cite were checked for support.
Abstract
SagA promotes immunotherapy response: The gut microbiome can influence the treatment outcome for cancer patients receiving PD-L1 immunotherapy, but the mechanisms underlying favorable responses are unclear. Griffin et al . found that a particular type of bacteria called enterococci enhance anti–PD-L1 immunotherapy in mice (see the Perspective by Ansaldo and Belkaid). The researchers show that enterococci secrete an enzyme called SagA that breaks down components of the bacterial cell wall. This process results in the release of muramyl peptide fragments, which in turn act as stimulatory molecules to promote signaling of the innate immune sensor protein NOD2 and improved immunotherapy responses. —PNK
Overview
CoChat Summary
TL;DR
Enterococcus species that produce secreted NlpC/p60 peptidoglycan hydrolases (SagA orthologs) improve checkpoint inhibitor responses in mouse tumor models by generating NOD2-active muropeptides. Engineering SagA into non-active E. faecalis or probiotic L. lactis, or giving synthetic MDP-l,d, reproduced antitumor benefit with anti-PD-L1.
Key findings
- In antibiotic-pretreated C57BL/6 mice bearing B16-F10 melanoma, oral E. faecium Com15 plus anti-PD-L1 reduced tumor size at high and low antibody doses versus anti-PD-L1 alone; all three E. faecium isolates tested were active, while no E. faecalis strain was. Similar fecal CFU across strains indicated the effect was not due to bacterial load.
- Active species E. durans, E. hirae, and E. mundtii shared peptidoglycan remodeling signatures and SagA orthologs; C-terminal NlpC/p60 domains were >90% identical, E. gallinarum’s closest protein was 67% identical, and E. faecalis lacked direct orthologs. Recombinant orthologs showed d,l-endopeptidase activity producing GMDP.
- E. faecalis engineered to express SagA plus anti-PD-L1 reduced B16-F10 growth, and this required NOD2. L. lactis expressing wild-type SagA matched E. faecium benefit, whereas catalytically inactive C443A SagA did not.
- Synthetic NOD2-active MDP-l,d with anti-PD-L1 significantly inhibited tumors, unlike MDP-l,l; scRNA-seq showed more intratumoral T lymphocytes, cytotoxic gene enrichment, a Cx3cr1/Nr4a1 monocyte increase, and NF-κB/inflammatory signatures.
Methods
- Mouse tumor models: SPF C57BL/6 mice (Jackson) pretreated two weeks with ampicillin, colistin, and streptomycin, then orally supplemented with enterococci, implanted with B16-F10 melanoma and treated with anti-PD-L1; separate Taconic SPF mice without antibiotics; MCA205 fibrosarcoma with anti-PD-1 and MC38 colorectal carcinoma with anti-CTLA-4; B16-OVA for flow cytometry.
- Bacterial and biochemical assays: HPLC-MS peptidoglycan fragment profiling, genomic/sequence alignments for SagA orthologs, Western blot for secretion, recombinant hydrolase activity assays, fecal/tissue CFU, and 16S rRNA microbiome analysis.
- Immune profiling: tumor-infiltrating lymphocytes quantified by flow cytometry; CD45+ tumor cells from MDP stereoisomer-treated mice analyzed by scRNA-seq and gene set enrichment.
Limitations
- Stated: the authors could not detect SagA orthologs in clinical metagenomic datasets before checkpoint blockade, which they attribute to low E. faecium genome coverage (9.34%). They also note uncertainty for the secretion-deficient L. lactis SagA strain, suggesting either low secreted SagA was sufficient or non-secreted SagA leaked via lysis.
- Evident: efficacy and mechanism data come from mouse tumor models and bacterial/muropeptide interventions, not human clinical trials; antibiotic pretreatment substantially depletes resident microbiota, although a non-antibiotic SPF model was also used.
- Evident: microbiome analyses showed incomplete antibiotic clearance and shifts over time, and some differential OTUs appeared in only one cage per condition, limiting microbiome attribution.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 7 Not checked · 63 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple analyses of the commensal microbiome from human cohorts treated with immunotherapies targeting PD-1 have revealed that the bacterial genus Enterococcus is enriched in responding patients (12, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the paper’s results (our copy labels the section Abstract; page unavailable), Enterococcus faecium is listed among species more abundant in responders. The paper reports enrichment of that species in a metastatic melanoma cohort, not enrichment of the genus Enterococcus as a whole across human cohorts. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, the gut microbiota has emerged as a potent new factor associated with the efficacy of anti–CTLA4, anti–PD-1, and anti–PD-L1 treatment (8-14).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Partly supportedcites [8] Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther P-L, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 350, 1079– 1084 (2015). 26541610 PMC4721659 sourceExperimental — accuracy not yet measured
The Abstract reports that gut microbiota composition influences the efficacy of CTLA-4 blockade, supporting the anti-CTLA-4 part of the sentence. The passages in our copy do not establish the same association for anti-PD-1 or anti-PD-L1 treatment, so this source does not support the full three-treatment claim. (LLM, conf=0.88)
- Partly supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 sourceExperimental — accuracy not yet measured
The supplied passages report that gut microbial composition influenced response to anti–PD-L1 treatment in mice. They discuss effects on the PD-1/PD-L1 axis more broadly, but do not report a direct anti–PD-1 treatment test; the CTLA-4 passage says the principles *could* apply to that pathway. Thus this source supports the anti–PD-L1 part, but not the claim that microbiota is established as associated with efficacy for all three treatments. (LLM, conf=0.88)
- Supportedcites [10] Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY, Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 19, 848– 855 (2017). 28923537 PMC5602478 source
The Introduction reports that gut microbiota influence responses to anti-PD-L1 and anti-CTLA4 therapy in mouse models. The Discussion reports gut microbial species associated with clinical response to anti-PD1 alone and combined anti-PD1/anti-CTLA4 therapy in melanoma patients. Together, these passages support the broad association claimed; page numbers are not provided in our copy. (LLM, conf=0.92)
- Supportedcites [11] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza I source
The paper reports an association between gut microbiome composition and anti-PD-1 response in melanoma patients, cites a similar finding in a small anti-CTLA-4 cohort, and reports improved anti-PD-L1 response in mice receiving fecal transplants from anti-PD-1 responders. These passages support the broad association claimed, although the evidence comes from different populations and study designs. (LLM, conf=0.87)
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
The paper reports an association between gut microbiota and anti–PD-1 response in metastatic melanoma patients, and its mouse experiments show differing anti–PD-L1 efficacy by microbiota (Abstract; Fig. 3F discussion; page unavailable). It included four anti–CTLA-4 recipients but reports no separate microbiota–efficacy association for that treatment. The anti–PD-L1 result is in mice, not patients. (LLM, conf=0.88)
- Supportedcites [14] Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, Weber JS, Osman I, Ahn J, Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019). 31597568 PMC6785875 source
The Background reports gut-microbiota effects on anti-CTLA-4 and anti-PD-L1 immunotherapy in mice and an association with clinical response in human melanoma patients. The Discussion describes associations with response to anti-PD-1 and anti-CTLA-4 treatment in melanoma patients. Together, these passages support the broad association attributed to this source. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“consistent with enhanced priming of a tumor antigen-specific immune response (9, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 source
The paper reports greater expansion of tumor-antigen-specific CD8+ T cells in tumor-draining lymph nodes and describes differences in T-cell priming in vivo (passages [1] and [2], page unavailable). This supports the cited interpretation that an increase in antigen-specific CD8+ T cells is consistent with enhanced priming. The paper studied SIY-specific cells; the citing paper’s OVA-specific observation is not itself attributed to this source. (LLM, conf=0.88)
- Supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 source
The passage describing the mouse tumor experiment reports more SIY-specific CD8+ T cells and explicitly interprets this as increased priming of tumor antigen-specific CD8+ T cells. The citation is attached to that interpretation, not to the citing study’s OVA-specific measurement. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Significant enrichment of hallmark gene sets (33) for inflammatory response and NF-κB signaling were found in the MDP-l,d dataset (Table S8).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [33] Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P, The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417– 425 (2015). 26771021 PMC4707969 source
The citation (33) is attached to 'hallmark gene sets' — an identification of the resource the citing authors ran enrichment against — not to their own MDP-l,d result. Our copy is exactly that source: the DISCUSSION states the hallmarks are released as the H Collection in MSigDB v5.0, every set name starting with HALLMARK, with Table 1 listing all 50 hallmarks and their descriptions; the RESULTS (Analysis of necrosis in glioblastoma) treat NFκB signaling as one of the biological themes covered, and the protein-phenotype validation section documents the immune/inflammatory hallmarks (IL6 JAK STAT3, IL2 STAT5 signaling). No passage of our copy reports anything about an 'MDP-l,d' dataset, which is consistent with that being the citing authors' own analysis rather than something attributed here. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We further confirmed that SagA orthologs are found in humans through alignment of the SagA NlpC/p60 domain with genomes within the Human Microbiome Project (24) (Fig. 2C, Table S5).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [24] Consortium THMJRS, A catalog of reference genomes from the human microbiome. Science. 328, 994– 999 (2010). 20489017 PMC2940224 source
The citation identifies the Human Microbiome Project genomes used for the citing authors’ alignment; the SagA result is presented as the citing authors’ own finding. The source’s Reference genome progress section describes the HMP-sequenced genomes, and its Data release section says their sequences and annotations were made available. (LLM, conf=0.91)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
54 more claims
Create a free account to see all 78 claims and to verify the 14 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, cause-effect relationships between the prevalence or relative abundance of particular taxa, and clinical regression or progression, have been shown in animal models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several probiotics or their products can inhibit tumor development by suppressing inflammation and promoting anti-tumor immune responses6,7.”
From Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Enterococcus expressed and secreted orthologs NlpC/p60 PG hydrolase SagA and could promote expression of the innate immune sensor protein nucleotide-binding oligomerization domain containing 2 (NOD2) and augment ICI antitumor efficacy [109] (Fig. 5F).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [109]
In the citing paper
“Thus, the peptidoglycan hydrolase SagA from Enterococcus faecium can be transferred into Lactococcus lactis to generate a probiotic strain that stimulates innate immune responses via NOD2 activation and promotes ICI antitumor activity in mice.26”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies
Nguyen, L.-T., Schmidt, H. A., von Haeseler, A., & Minh, B. Q. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msu300 · Cited by 26,046
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses
Capella-Gutiérrez, S., Silla-Martínez, J. M., & Gabaldón, T. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp348 · Cited by 12,751
UFBoot2: Improving the Ultrafast Bootstrap Approximation
Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q., & Vinh, L. S. (2018) · Molecular Biology and Evolution · doi:10.1093/molbev/msx281 · Cited by 10,881
The Phyre2 web portal for protein modeling, prediction and analysis
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., & Sternberg, M. J. E. (2015) · Nature Protocols · doi:10.1038/nprot.2015.053 · Cited by 9,652
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839
Deciphering key features in protein structures with the new ENDscript server
Robert, X., & Gouet, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku316 · Cited by 7,053
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Interactive Tree Of Life (iTOL) v4: recent updates and new developments
Letunic, I., & Bork, P. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz239 · Cited by 5,925
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
W-IQ-TREE: a fast online phylogenetic tool for maximum likelihood analysis
Trifinopoulos, J., Nguyen, L.-T., von Haeseler, A., & Minh, B. Q. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw256 · Cited by 5,504
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Ribosomal Database Project: data and tools for high throughput rRNA analysis
Cole, J. R., Wang, Q., Fish, J. A., Chai, B., McGarrell, D. M., Sun, Y., Brown, C. T., Porras-Alfaro, A., Kuske, C. R., & Tiedje, J. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1244 · Cited by 4,367
The EMBL-EBI search and sequence analysis tools APIs in 2019
Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
PHASTER: a better, faster version of the PHAST phage search tool
Arndt, D., Grant, J. R., Marcu, A., Sajed, T., Pon, A., Liang, Y., & Wishart, D. S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw387 · Cited by 3,557
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Finak, G., McDavid, A., Yajima, M., Deng, J., Gersuk, V., Shalek, A. K., Slichter, C. K., Miller, H. W., McElrath, M. J., Prlic, M., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0844-5 · Cited by 3,159
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Defining trained immunity and its role in health and disease
Netea, M. G., Domínguez-Andrés, J., Barreiro, L. B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L. A. B., van der Meer, J. W. M., Mhlanga, M. M., Mulder, W. J. M., et al. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0285-6 · Cited by 2,690
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
McCarthy, D. J., Campbell, K. R., Lun, A. T. L., & Wills, Q. F. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btw777 · Cited by 1,852
Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract
Kobayashi, K. S., Chamaillard, M., Ogura, Y., Henegariu, O., Inohara, N., Nuñez, G., & Flavell, R. A. (2005) · Science · doi:10.1126/science.1104911 · Cited by 1,776
Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L. A. B., Ifrim, D. C., Saeed, S., Jacobs, C., van Loenhout, J., de Jong, D., Stunnenberg, H. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202870109 · Cited by 1,728
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity
Clarke, T. B., Davis, K. M., Lysenko, E. S., Zhou, A. Y., Yu, Y., & Weiser, J. N. (2010) · Nature Medicine · doi:10.1038/nm.2087 · Cited by 1,154
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
SINTAX: a simple non-Bayesian taxonomy classifier for 16S and ITS sequences
Edgar, R. C. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/074161 · Cited by 973
Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
Duan, Y., Llorente, C., Lang, S., Brandl, K., Chu, H., Jiang, L., White, R. C., Clarke, T. H., Nguyen, K., Torralba, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1742-x · Cited by 844
Translocation of a gut pathobiont drives autoimmunity in mice and humans
Manfredo Vieira, S., Hiltensperger, M., Kumar, V., Zegarra-Ruiz, D., Dehner, C., Khan, N., Costa, F. R. C., Tiniakou, E., Greiling, T., Ruff, W., et al. (2018) · Science · doi:10.1126/science.aar7201 · Cited by 839
NOD1 and NOD2: Signaling, Host Defense, and Inflammatory Disease
Caruso, R., Warner, N., Inohara, N., & Núñez, G. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.010 · Cited by 830
The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal
Lieberman, J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1083 · Cited by 789
Frankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
A Catalog of Reference Genomes from the Human Microbiome
The Human Microbiome Jumpstart Reference Strains Consortium, Nelson, K. E., Weinstock, G. M., Highlander, S. K., Worley, K. C., Creasy, H. H., Wortman, J. R., Rusch, D. B., Mitreva, M., Sodergren, E., et al. (2010) · Science · doi:10.1126/science.1183605 · Cited by 702
NOD proteins: regulators of inflammation in health and disease
Philpott, D. J., Sorbara, M. T., Robertson, S. J., Croitoru, K., & Girardin, S. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3565 · Cited by 668
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 646
The Genus Enterococcus: Between Probiotic Potential and Safety Concerns—An Update
Hanchi, H., Mottawea, W., Sebei, K., & Hammami, R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01791 · Cited by 569
Kommineni, S., Bretl, D. J., Lam, V., Chakraborty, R., Hayward, M., Simpson, P., Cao, Y., Bousounis, P., Kristich, C. J., & Salzman, N. H. (2015) · Nature · doi:10.1038/nature15524 · Cited by 458
Lactose drives Enterococcus expansion to promote graft-versus-host disease
Stein-Thoeringer, C. K., Nichols, K. B., Lazrak, A., Docampo, M. D., Slingerland, A. E., Slingerland, J. B., Clurman, A. G., Armijo, G., Gomes, A. L. C., Shono, Y., et al. (2019) · Science · doi:10.1126/science.aax3760 · Cited by 384
Vermassen, A., Leroy, S., Talon, R., Provot, C., Popowska, M., & Desvaux, M. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00331 · Cited by 348
Lee, S.-H., Cho, S.-Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.-J., Jeon, B.-N., Jang, M., An, C., Lee, S., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-020-00831-6 · Cited by 325
Fidler, I. J., Sone, S., Fogler, W. E., & Barnes, Z. L. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1680 · Cited by 324
Minimal Requirements for Exponential Growth of Lactococcus lactis
Jensen, P. R., & Hammer, K. (1993) · Applied and Environmental Microbiology · doi:10.1128/aem.59.12.4363-4366.1993 · Cited by 318
Tracing the Enterococci from Paleozoic Origins to the Hospital
Lebreton, F., Manson, A. L., Saavedra, J. T., Straub, T. J., Earl, A. M., & Gilmore, M. S. (2017) · Cell · doi:10.1016/j.cell.2017.04.027 · Cited by 302
Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J. (2019) · Genome Medicine · doi:10.1186/s13073-019-0672-4 · Cited by 263
Priem, B., van Leent, M. M. T., Teunissen, A. J. P., Sofias, A. M., Mourits, V. P., Willemsen, L., Klein, E. D., Oosterwijk, R. S., Meerwaldt, A. E., Munitz, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.059 · Cited by 222
A secreted bacterial peptidoglycan hydrolase enhances tolerance to enteric pathogens
Rangan, K. J., Pedicord, V. A., Wang, Y.-C., Kim, B., Lu, Y., Shaham, S., Mucida, D., & Hang, H. C. (2016) · Science · doi:10.1126/science.aaf3552 · Cited by 160
Self-citationKim, B., Wang, Y.-C., Hespen, C. W., Espinosa, J., Salje, J., Rangan, K. J., Oren, D. A., Kang, J. Y., Pedicord, V. A., & Hang, H. C. (2019) · eLife · doi:10.7554/elife.45343 · Cited by 120
Self-citationHuang, Z., Wang, J., Xu, X., Wang, H., Qiao, Y., Chu, W. C., Xu, S., Chai, L., Cottier, F., Pavelka, N., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0381-1 · Cited by 107
Wong, Q. N. Y. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni059 · Cited by 103
Pedicord, V. A., Lockhart, A. A. K., Rangan, K. J., Craig, J. W., Loschko, J., Rogoz, A., Hang, H. C., & Mucida, D. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai7732 · Cited by 99
Self-citationTeng, F., Kawalec, M., Weinstock, G. M., Hryniewicz, W., & Murray, B. E. (2003) · Infection and Immunity · doi:10.1128/iai.71.9.5033-5041.2003 · Cited by 96
Lessard, A.-J., LeBel, M., Egarnes, B., Préfontaine, P., Thériault, P., Droit, A., Brunet, A., Rivest, S., & Gosselin, J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.009 · Cited by 70
Replacement recombination in Lactococcus lactis
Leenhouts, K. J., Kok, J., & Venema, G. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.15.4794-4798.1991 · Cited by 68
Mohamed, J. A., Teng, F., Nallapareddy, S. R., & Murray, B. E. (2006) · The Journal of Infectious Diseases · doi:10.1086/498871 · Cited by 53
Lactic Acid Bacteria for Delivery of Endogenous or Engineered Therapeutic Molecules
Bron, P. A., & Kleerebezem, M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01821 · Cited by 45
Asano, J., Tada, H., Onai, N., Sato, T., Horie, Y., Fujimoto, Y., Fukase, K., Suzuki, A., Mak, T. W., & Ohteki, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900726 · Cited by 45
Sasaki, Y., Ito, Y., & Sasaki, T. (2004) · Applied and Environmental Microbiology · doi:10.1128/aem.70.3.1858-1864.2004 · Cited by 32
NOD2 modulates immune tolerance via the GM-CSF–dependent generation of CD103 + dendritic cells
Prescott, D., Maisonneuve, C., Yadav, J., Rubino, S. J., Girardin, S. E., & Philpott, D. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912866117 · Cited by 26
Simons, G., Nijhuis, M., & de Vos, W. M. (1993) · Journal of Bacteriology · doi:10.1128/jb.175.16.5168-5175.1993 · Cited by 26
Biochemical analysis of NlpC/p60 peptidoglycan hydrolase activity
Kim, B.-C., Espinosa, J., & Hang, H. C. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2020.02.017 · Cited by 11
Self-citation
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
“A recent study has shed some light: certain strains of Enterococcus (and other bacteria) express a peptidoglycan hydrolyase called SagA that releases mucopeptides from the bacterial wall, which can then circulate systemically and activate the NOD2 pattern receptor, which in turn can enhance T-cell responses and the ef…”
BackgroundGut microbiome and health: mechanistic insights
de Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022) · Gut · doi:10.1136/gutjnl-2021-326789 · Cited by 2,388
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Metadata
- Authors
- Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C.
- Affiliations
- Scripps Research Institute (US)
- Rockefeller University (US)
- Rise Therapeutics, 1405 Research Blvd. Suite 220, Rockville, MD 20850, USA.
- Corresponding author
- Hang, Howard C.
- ORCID
- Venue
- Science
- Published
- 2021-08-27
- Volume
- 373
- Issue
- 6558
- Pages
- 1040-1046
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9503018
- OpenAlex
- W3194929095
- Cited by
- 366
- References
- 75
- Citations by year
- 2026: 69 · 2025: 71 · 2024: 83 · 2023: 80 · 2022: 52 · 2021: 10
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (1R01CA245292-01, A1070084)
- Melanoma Research Foundation (Career Development Award)
- ASCRS Research Foundation (HCFR-19-03-02)
- Hope Funds for Cancer Research (HCFR-19-03-02)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- Enterococcus, sagas, peptidoglycan remodeling, cancer immunotherapy, PD-L1 blockade, gut microbiota, muramyl peptides, NOD2 signaling, innate immunity, bacterial cell wall degradation
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Bacterial Proteins, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, N-Acetylmuramoyl-L-alanine Amidase, Peptide Fragments, Peptidoglycan, Enterococcus faecalis, Signal Transduction, Enterococcus, Enterococcus faecium, Probiotics, Mice, Nod2 Signaling Adaptor Protein, Bacterial Load, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.